Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

th several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 will not be successful, that NP-1 will not receive regulatory approval or achieve significant
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... of Arts and Sciences has received a major ... , Mathew M. Maye, associate professor of chemistry, ... the National Science Foundation (NSF). The award supports ... the results of which may impact gas storage, ... , Maye,s approach is novel, in that he ...
(Date:7/21/2014)... , July 21, 2014  Mike Patterson, CEO ... $1.6 million in Series Seed B funding to ... sensors for the life science, defense, intelligence, and ... Partners led the round and was joined by ... Said Patterson , "This round of funding ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Sleep ... quality are closely correlated with depression. According to ... Health: "About three quarters of depressed patients ... about 40% of young depressed adults and 10% ... The symptoms cause huge distress, have a major ...
(Date:7/20/2014)... (PRWEB) July 20, 2014 NSG ... quartz glass optics, and spectrophotometer calibration ... years, NSG has released many products that have ... product has been their solid-state calibration standards. , ... standards since their release in 2008. NSG ...
Breaking Biology Technology:Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3How NSG Precision Cells Spectrophotometer Calibration Standards Makes NIR Work Easier 2How NSG Precision Cells Spectrophotometer Calibration Standards Makes NIR Work Easier 3
... Switzerland, May 16 Arpida Ltd.,(SWX: ARPN) today announced ... for review the New Drug Application (NDA) for,intravenous iclaprim ... (cSSSI). Arpida completed the submission of the NDA to,the ... ten month review to,the iclaprim NDA and has established ...
... Million - ... - Gross Profit Up; Net Loss Down -, TUSTIN, ... a vertically integrated specialty pharmaceutical company headquartered,in Tustin, California, with ... subsidiary Jade Pharmaceutical Inc. (JPI),the Company engages in the research, ...
... Principle Reached to Terminate Marketing Agreement with Triax ... on Most Favorable Terms, NAPA, Calif., May 15 ... company engaged in the development,of technologies that target the ... quarter ended March 31, 2008 and an agreement in,principle ...
Cached Biology Technology:Arpida Announces FDA Acceptance of the Iclaprim New Drug Application 2Arpida Announces FDA Acceptance of the Iclaprim New Drug Application 3AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million 2AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million 3Senetek PLC Reports First Quarter 2008 Financial Results 2Senetek PLC Reports First Quarter 2008 Financial Results 3
(Date:7/21/2014)... cheating in science are among the topics to ... experts in Montreal at the three International Union ... to August 1, 2014. Some 2,000 participants from ... 14th International Congress of Bacteriology and Applied Microbiology, ... Microbiology, and the 16th International Congress of Virology. ...
(Date:7/21/2014)... in areas across Riau province on Sunday, July 20, ... a decline in rainfall. The number of detected ... had been reported one day prior, which had reached ... six regencies and municipalities, most of which were in ... it creates could potentially spread via winds to Malaysia ...
(Date:7/21/2014)... that uses extracts from seeds of Moringa oleifa trees ... 90% to 99%. The hardy trees that are drought ... Asia, and Latin America. , The protocol, which is ... review, is low-cost and efficient, making it especially useful ... who are presently drinking highly turbid and contaminated water. ...
Breaking Biology News(10 mins):Montreal hosts International Union of Microbiology Societies congresses 2
... must address ecological threats, a top international scientific meeting ... the planet,s natural limits in a striking parallel to ... a subprime loan," Dr. Johan Rockstrm of the Stockholm ... risks of both kinds of crises in the future. ...
... a multi-year $1 million sponsored research agreement with ... the maker of Smart Balance buttery spread and ... cholesterol through a patented blend of natural vegetable ... entered into a collaboration and license to develop ...
... 6, 2008, Cambridge, UK ,Discussion of a man,s background, ... and The City episodes in the future, it could ... Risk of developing type 2 diabetes and metabolic ... this background has in turn been influenced by environment and ...
Cached Biology News:Top scientific meeting urges coordinated response to economic and environmental crises 2Brandeis and Smart Balance team up to advance heart-healthy research 2Coping and copulation behavior may help calculate diabetes risk 2
... Conjugated peptides or recombinant proteins are used ... antibodies in 2 rabbits. pre-immune and three ... until the titer reaches 1:4,000 Western blot ... G purification Antibodies are eluted using both ...
... analysis & visualization software. ... multiple samples. Combine Sequest ... increased confidence. Get more ... from your MS/MS experiments.14 ...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
Biology Products: